Gene News and Research

Latest Gene News and Research

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.

31 Jan 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

EU grants 3.3 million to AMP for gene therapy development against AIP

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Union has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria.

31 Jan 2011

EA receives CLIA certification for clinical laboratory testing

Expression Analysis, a leading provider of genomic services for clinical trials and research, announced today it has received CLIA certification. This milestone comes as the company enters its tenth year of providing genomic expertise; something the company refers to as "Genomic Know-How.

29 Jan 2011

ISU researchers study parasites that cause NTDs in humans

Richard Martin, DVM, PhD, a biomedical sciences professor at Iowa State University's College of Veterinary Medicine, has devoted his 35-year career to studying nematode parasites. These parasites infect approximately one-quarter of the world population, producing debilitating symptoms that devastate the lives and economies of many of the world's underdeveloped and impoverished areas.

29 Jan 2011

OREF, Biomet donate $1.3 million for medical education programs in orthopaedic surgery

Biomet, and the Orthopaedic Research and Education Foundation announced today Biomet's 2011 donation of $1.3 million for funding graduate medical education programs in orthopaedic surgery.

29 Jan 2011

GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender, a $12.5 million senior secured multi-draw term loan facility to XDx, Inc. The financing provides XDx with working capital to expand the commercialization of its FDA-cleared, innovative, noninvasive AlloMap molecular diagnostic test and pursue the development of other gene expression-based tests for autoimmune diseases including lupus.

29 Jan 2011

Genetic study helps investigators solve medical mysteries

The mystery began in 1976. Adolfo Pampena was diagnosed with a rare form of cancer that caused a strange combination of symptoms and was associated with the occurrence of multiple tumours in his stomach and colon. His medical team was stumped and was unable to answer the most important questions for him and his family: the cause of his disease and the risk for future generations.

29 Jan 2011

Athersys enters definitive agreements to sell common stock, warrants

Athersys, announced today that it has entered into definitive agreements with certain investors to sell 4,366,667 shares of its common stock and warrants to purchase up to an additional 1,310,000 shares of common stock in a registered direct offering for gross proceeds of approximately $13.1 million, before deducting fees and offering expenses.

29 Jan 2011

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck Inc. today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

29 Jan 2011

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Research from the University of California, San Diego School of Medicine provides new clues for the compulsive behavior and cognitive defects associated with a rare childhood neurological disease called Lesch-Nyhan Disease.

29 Jan 2011

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

XDx, a San Francisco-based molecular diagnostics company focused on non-invasive gene expression-based tests for the monitoring of organ transplant rejection and autoimmune diseases, announced today that it has established a $12.5 million senior secured multi-draw term loan facility with GE Capital, Healthcare Financial Services.

28 Jan 2011

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration approved Rituxan as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.

28 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock.

28 Jan 2011

New molecular player responsible for regulation of appetite and metabolism

A study by researchers at Mayo Clinic's campus in Florida and Washington University School of Medicine adds a new twist to the body of evidence suggesting human obesity is due in part to genetic factors. While studying hormone receptors in laboratory mice, neuroscientists identified a new molecular player responsible for the regulation of appetite and metabolism.

28 Jan 2011

Protein Erk necessary for nerve fibers to be wrapped with myelin

Researchers at the University of North Carolina at Chapel Hill have pinpointed a crucial function for a key player in the development of the nervous system. They found that this player - a protein called Erk - is necessary for nerve fibers to be wrapped with an insulating substance called myelin, which allows messages to be sent from the brain to the peripheral limbs and back again.

28 Jan 2011

Single DNA variation linked to decreased risk of coronary disease in African-Americans

A team of scientists at Johns Hopkins and elsewhere has discovered that a single alteration in the genetic code of about a fourth of African-Americans helps protect them from coronary artery disease, the leading cause of death in Americans of all races.

28 Jan 2011

Gene News and Research

Latest Gene News and Research

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

EU grants 3.3 million to AMP for gene therapy development against AIP

EA receives CLIA certification for clinical laboratory testing

ISU researchers study parasites that cause NTDs in humans

OREF, Biomet donate $1.3 million for medical education programs in orthopaedic surgery

GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

Genetic study helps investigators solve medical mysteries

Athersys enters definitive agreements to sell common stock, warrants

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

Research provides new clues for compulsive behavior, cognitive defects linked with LND

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

New molecular player responsible for regulation of appetite and metabolism

Protein Erk necessary for nerve fibers to be wrapped with myelin

Single DNA variation linked to decreased risk of coronary disease in African-Americans

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation